全球配藥藥房市場2022-2030:市場規模(按治療領域、產品、應用、配藥類型、無菌性、分銷渠道)、區域展望、COVID-19影響、價格趨勢、競爭市場份額、預測
市場調查報告書
商品編碼
1123575

全球配藥藥房市場2022-2030:市場規模(按治療領域、產品、應用、配藥類型、無菌性、分銷渠道)、區域展望、COVID-19影響、價格趨勢、競爭市場份額、預測

Compounding Pharmacies Market Size, By Therapeutic Area, Product, Application, Compounding Type, Sterility, Distribution Channel, Regional Outlook, Price Trends, Competitive Market Share & Forecast, 2022-2030

出版日期: | 出版商: Global Market Insights Inc. | 英文 530 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於個性化醫療在發達國家的普及,預計到 2030 年配藥藥房市場將顯著增長。

此外,人口老齡化加劇和藥品短缺預計將在整個預測期內進一步推動市場增長。

按治療領域,預計皮膚科部門在預測期內的複合年增長率約為 6.4%。日益增長的皮膚問題,如皮膚老化和曬傷,以及對健康皮膚的日益增長的需求是推動皮膚科製劑需求的主要因素。

在本報告中,我們調查了全球配藥藥房市場並提供了市場概況,分析了市場增長的各種影響因素、法律和監管環境、報銷情況、市場規模的趨勢和預測、各個細分市場/地區/major 按國家、競爭環境、主要公司概況等匯總。

內容

第一章調查方法及範圍

第 2 章執行摘要

第 3 章配藥行業注意事項

  • 行業分類
  • 行業情況
  • 工業生態系統分析
  • 影響行業的因素
    • 驅動程序
    • 潛在風險和問題
  • 增長分析
  • 監管狀況
  • 贖回情況
  • COVID-19 影響分析
  • 波特分析
  • 競爭格局,
  • PESTEL 分析

第 4 章配藥市場:按治療領域劃分

  • 主要趨勢
  • 激素替代品
  • 疼痛管理
  • 皮膚科
  • 特殊藥物
  • 膳食補充劑
  • 其他

第 5 章配藥市場:按產品分類

  • 主要趨勢
  • 口服劑
    • 固體配方
    • 液體配方
  • 外用藥劑
    • 藥膏
    • 奶油
    • 凝膠
    • 粘貼
    • 其他
  • 栓劑
    • 栓劑
    • 灌腸
    • 其他
  • 家長代理
    • LVP
    • 高級副總裁
  • 鼻用劑
  • 眼藥水
  • 滴耳劑

第 6 章配藥市場:按應用分類

  • 主要趨勢
  • 兒科
  • 成人
  • 老年人
  • 動物

第 7 章配藥市場:按配藥類型

  • 主要趨勢
  • PIA
  • CUPM
  • 掌上電腦
  • 其他

第 8 章配藥市場:無菌性別

  • 主要趨勢
  • 無菌
  • 非無菌

第 9 章。配藥市場:按分銷渠道

  • 主要趨勢
  • 醫院藥房
  • 配藥藥房
  • 其他

第 10 章配藥市場:按地區劃分

  • 主要趨勢
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第 11 章公司簡介

  • 戰略信息中心
  • Athenex Pharma Solutions(Athenex Inc.)
  • B. Braun SE
  • Clinigen Limited
  • Dougherty's Pharmacy, Inc.
  • Fagron
  • Fresenius Kabi
  • Institutional Pharmacy Solutions
  • Lorraine's Pharmacy
  • McGuff Company Inc.(McGuff Compounding Pharmacy Services)
  • Nephron Pharmaceuticals Corporation
  • Pencol Compounding Pharmacy
  • Rx3 Compounding Pharmacy
  • Triangle Compounding Pharmacies
  • Wedgewood Village Pharmacy, Inc.
簡介目錄
Product Code: 749

The compounding pharmacies market is speculated to grow massively by 2030 owing to widespread adoption of customized medicine in developed regions. In addition, expanding geriatric population, along with a shortage of drugs, is likely to further propel market growth through the forecast period.

The emergence of the COVID-19 pandemic provided the industry with new opportunities to prosper in recent years. Increasing demand for medications from hospital and compounding pharmacies to curb the spread of the coronavirus infection escalated the utilization of compounded drugs. Furthermore, government authorization to maintain the availability of these drugs aided market expansion.

Moreover, key players in the market have been engaging in rigorous R&D and strategic acquisitions and collaborations to expand their customer base and improve their industry standing. For instance, in March 2022, B. Braun, a German medical and pharmaceutical company, acquired Intermedt Medizin & Technik GmbH, an expert in the preparation of dialysis concentrates. The acquisition was intended to aid the company in expanding its business in the field of dialysis concentrates.

The compounding pharmacies market has been bifurcated in terms of product, therapeutic area, application, sterility, compounding type, distribution channel, and region.

With respect to therapeutic area, the industry has been divided into nutritional supplements, hormone replacement, dermatology, pain management, specialty drugs, and others. The dermatology segment is expected to grow at approximately 6.4% CAGR over the analysis timeframe. Growing skin-related concerns viz., skin aging and sunburns, coupled with soaring need for healthy skin, are major factors that are poised to drive the demand for compounding medicines for dermatological usage. Additionally, the ability of compounded dermatological drugs to accommodate individual needs and overcome issues related to allergies and sensitivities caused by commercially available skin care medications is set to boost segmental progress.

The compounding pharmacies market has been classified based on product into oral, topical, parenteral, rectal, nasal, otic, and ophthalmic. The topical segment size was registered at over $1,727.2 million in 2021 and is slated to attain substantial gains by 2030. The growth is attributed to ease of drug delivery, drug formulations, and rising demand for ointments, gels, creams, patches, lotions, and sprays, especially for pain management owing to their faster action at the site of application. Moreover, prominent R&D activities for the development of innovative topical medications using compounding pharmacies to cater to specific patient requirements are also projected to propel segmental expansion.

From application point of reference, the compounding pharmacies market has been segregated into pediatric, geriatric, adult, and veterinary. In 2021, the pediatric segment accounted for above $1,653.2 million valuation and is estimated to record significant expansion in the coming years. Several benefits of compounded medications, such as dose alteration, ingredient alteration, and the advantage of altering the route of administration, are likely to increase the demand for compounded medications for pediatric usage.

In the regional context, the Middle East & Africa compounding pharmacies industry was valued at nearly $179.4 million in 2021. Burgeoning healthcare expenditure, favorable government initiatives in the healthcare segment, and cost-effectiveness of compounded medications are primed to accelerate the growth of the MEA compounding pharmacies market in the future.

Table of Contents

Chapter 1 Methodology

  • 1.1 Methodology
  • 1.2 Market definitions
  • 1.3 Forecast parameters
  • 1.4 Data sources
    • 1.4.1 Secondary
      • 1.4.1.1 Paid sources
      • 1.4.1.2 Public sources
    • 1.4.2 Primary

Chapter 2 Executive Summary

  • 2.1 Compounding pharmacies industry 360 degree synopsis, 2017 - 2030
    • 2.1.1 Business trends
    • 2.1.2 Therapeutic area trends
    • 2.1.3 Product trends
    • 2.1.4 Application trends
    • 2.1.5 Compounding type trends
    • 2.1.6 Sterility trends
    • 2.1.7 Distribution channel trends
    • 2.1.8 Regional trends

Chapter 3 Compounding Pharmacies Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2030
  • 3.3 Industry ecosystem analysis
    • 3.3.1 Distribution channel analysis
  • 3.4 Industry impact forces
    • 3.4.1 Growth drivers
      • 3.4.1.1 Rising geriatric population and improved life expectancy across the globe
      • 3.4.1.2 Rising adoption of customized medicine in the developed regions
      • 3.4.1.3 Shortage of drugs across the globe
      • 3.4.1.4 Benefits of compounded medication
      • 3.4.1.5 Growing drug failure rate
    • 3.4.2 Industry pitfalls & challenges
      • 3.4.2.1 Lack of skilled lab technicians and pharmacists in developed economies
      • 3.4.2.2 High cost of equipment and maintenance of sterile environment
      • 3.4.2.3 Volatile regulatory scenario
      • 3.4.2.4 Consumer perception towards compounded drugs
  • 3.5 Growth potential analysis
    • 3.5.1 By therapeutic area
    • 3.5.2 By product
    • 3.5.3 By application
    • 3.5.4 By compounding type
    • 3.5.5 By sterility
    • 3.5.6 By distribution type
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
    • 3.6.3 Australia
  • 3.7 Reimbursement landscape
    • 3.7.1 U.S.
    • 3.7.2 Europe
    • 3.7.3 Australia
  • 3.8 COVID- 19 impact analysis
  • 3.9 Porter's analysis
  • 3.10 Competitive landscape, 2021
    • 3.10.1 Company matrix analysis, 2021
  • 3.11 PESTEL analysis

Chapter 4 Compounding Pharmacies Market, By Therapeutic Area

  • 4.1 Key segment trends
  • 4.2 Hormone replacement
    • 4.2.1 Market size, by region, 2017-2030 (USD Million)
  • 4.3 Pain management
    • 4.3.1 Market size, by region, 2017-2030 (USD Million)
  • 4.4 Dermatology applications
    • 4.4.1 Market size, by region, 2017-2030 (USD Million)
  • 4.5 Specialty drugs
    • 4.5.1 Market size, by region, 2017-2030 (USD Million)
  • 4.6 Nutritional supplements
    • 4.6.1 Market size, by region, 2017-2030 (USD Million)
  • 4.7 Others
    • 4.7.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Compounding Pharmacies Market, By Product

  • 5.1 Key segment trends
  • 5.2 Oral
    • 5.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.2 Solid preparations
      • 5.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.2 Tablets
        • 5.2.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.3 Capsules
        • 5.2.2.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.4 Granules
        • 5.2.2.4.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.5 Powder
        • 5.2.2.5.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.2.6 Others
        • 5.2.2.6.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.3 Liquid preparations
      • 5.2.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.2 Solution
        • 5.2.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.3 Suspension
        • 5.2.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.4 Emulsion
        • 5.2.3.4.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.5 Syrup
        • 5.2.3.5.1 Market size, by region, 2017-2030 (USD Million)
      • 5.2.3.6 Others
        • 5.2.3.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.3 Topical
    • 5.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.2 Ointments
      • 5.3.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.3 Creams
      • 5.3.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.4 Gels
      • 5.3.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.5 Pastes
      • 5.3.5.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.6 Others
      • 5.3.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.4 Rectal
    • 5.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.2 Suppositories
      • 5.4.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.3 Enema
      • 5.4.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.4 Others
      • 5.4.4.1 Market size, by region, 2017-2030 (USD Million)
  • 5.5 Parenteral
    • 5.5.1 Market size, by region, 2017-2030 (USD Million)
    • 5.5.2 LVP
      • 5.5.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.5.3 SVP
      • 5.5.3.1 Market size, by region, 2017-2030 (USD Million)
  • 5.6 Nasal
    • 5.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.7 Ophthalmic
    • 5.7.1 Market size, by region, 2017-2030 (USD Million)
  • 5.8 Otic
    • 5.8.1 Market size, by region, 2017-2030 (USD Million)

Chapter 6 Compounding Pharmacies Market, By Application

  • 6.1 Key segment trends
  • 6.2 Pediatric
    • 6.2.1 Market size, by region, 2017-2030 (USD Million)
  • 6.3 Adult
    • 6.3.1 Market size, by region, 2017-2030 (USD Million)
  • 6.4 Geriatric
    • 6.4.1 Market size, by region, 2017-2030 (USD Million)
  • 6.5 Veterinary
    • 6.5.1 Market size, by region, 2017-2030 (USD Million)

Chapter 7 Compounding Pharmacies Market, By Compounding Type

  • 7.1 Key segment trends
  • 7.2 Pharmaceutical Ingredient Alteration (PIA)
    • 7.2.1 Market size, by region, 2017-2030 (USD Million)
  • 7.3 Currently Unavailable Pharmaceutical Manufacturing (CUPM)
    • 7.3.1 Market size, by region, 2017-2030 (USD Million)
  • 7.4 Pharmaceutical Dosage Alteration (PDA)
    • 7.4.1 Market size, by region, 2017-2030 (USD Million)
  • 7.5 Others
    • 7.5.1 Market size, by region, 2017-2030 (USD Million)

Chapter 8 Compounding Pharmacies Market, By Sterility

  • 8.1 Key segment trends
  • 8.2 Sterile
    • 8.2.1 Market size, by region, 2017-2030 (USD Million)
  • 8.3 Non-sterile
    • 8.3.1 Market size, by region, 2017-2030 (USD Million)

Chapter 9 Compounding Pharmacies Market, By Distribution Channel

  • 9.1 Key segment trends
  • 9.2 Hospital pharmacy
    • 9.2.1 Market size, by region, 2017-2030 (USD Million)
  • 9.3 Compounding pharmacy
    • 9.3.1 Market size, by region, 2017-2030 (USD Million)
  • 9.4 Others
    • 9.4.1 Market size, by region, 2017-2030 (USD Million)

Chapter 10 Compounding Pharmacies Market, By Region

  • 10.1 Key regional trends
  • 10.2 North America
    • 10.2.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.2.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.2.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.2.3.1 Market size, by oral, 2017 - 2030
        • 10.2.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.2.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.2.3.2 Market size, by topical, 2017 - 2030
      • 10.2.3.3 Market size, by rectal, 2017 - 2030
      • 10.2.3.4 Market size, by parenteral, 2017 - 2030
    • 10.2.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.2.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.2.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.2.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.2.8 U.S.
      • 10.2.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.2.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.2.8.2.1 Market size, by oral, 2017 - 2030
        • 10.2.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.2.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.2.8.2.2 Market size, by topical, 2017 - 2030
        • 10.2.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.2.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.2.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.2.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.2.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.2.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.2.9 Canada
      • 10.2.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.2.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.2.9.2.1 Market size, by oral, 2017 - 2030
        • 10.2.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.2.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.2.9.2.2 Market size, by topical, 2017 - 2030
        • 10.2.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.2.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.2.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.2.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.2.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.2.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.3 Europe
    • 10.3.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.3.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.3.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.3.3.1 Market size, by oral, 2017 - 2030
        • 10.3.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.3.3.2 Market size, by topical, 2017 - 2030
      • 10.3.3.3 Market size, by rectal, 2017 - 2030
      • 10.3.3.4 Market size, by parenteral, 2017 - 2030
    • 10.3.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.3.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.3.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.3.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.8 Germany
      • 10.3.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.8.2.1 Market size, by oral, 2017 - 2030
        • 10.3.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.8.2.2 Market size, by topical, 2017 - 2030
        • 10.3.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.9 UK
      • 10.3.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.9.2.1 Market size, by oral, 2017 - 2030
        • 10.3.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.9.2.2 Market size, by topical, 2017 - 2030
        • 10.3.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.10 France
      • 10.3.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.10.2.1 Market size, by oral, 2017 - 2030
        • 10.3.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.10.2.2 Market size, by topical, 2017 - 2030
        • 10.3.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.11 Italy
      • 10.3.11.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.11.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.11.2.1 Market size, by oral, 2017 - 2030
        • 10.3.11.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.11.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.11.2.2 Market size, by topical, 2017 - 2030
        • 10.3.11.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.11.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.11.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.11.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.11.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.11.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.12 Spain
      • 10.3.12.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.12.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.12.2.1 Market size, by oral, 2017 - 2030
        • 10.3.12.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.12.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.12.2.2 Market size, by topical, 2017 - 2030
        • 10.3.12.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.12.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.12.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.12.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.12.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.12.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.13 Poland
      • 10.3.13.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.13.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.13.2.1 Market size, by oral, 2017 - 2030
        • 10.3.13.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.13.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.13.2.2 Market size, by topical, 2017 - 2030
        • 10.3.13.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.13.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.13.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.13.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.13.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.13.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.14 Ukraine
      • 10.3.14.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.14.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.14.2.1 Market size, by oral, 2017 - 2030
        • 10.3.14.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.14.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.14.2.2 Market size, by topical, 2017 - 2030
        • 10.3.14.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.14.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.14.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.14.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.14.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.14.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.15 Greece
      • 10.3.15.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.15.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.15.2.1 Market size, by oral, 2017 - 2030
        • 10.3.15.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.15.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.15.2.2 Market size, by topical, 2017 - 2030
        • 10.3.15.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.15.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.15.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.15.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.15.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.15.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.16 Sweden
      • 10.3.16.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.16.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.16.2.1 Market size, by oral, 2017 - 2030
        • 10.3.16.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.16.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.16.2.2 Market size, by topical, 2017 - 2030
        • 10.3.16.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.16.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.16.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.16.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.16.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.16.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.17 Norway
      • 10.3.17.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.17.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.17.2.1 Market size, by oral, 2017 - 2030
        • 10.3.17.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.17.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.17.2.2 Market size, by topical, 2017 - 2030
        • 10.3.17.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.17.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.17.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.17.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.17.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.17.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.18 Belgium
      • 10.3.18.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.18.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.18.2.1 Market size, by oral, 2017 - 2030
        • 10.3.18.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.18.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.18.2.2 Market size, by topical, 2017 - 2030
        • 10.3.18.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.18.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.18.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.18.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.18.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.18.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.19 Czech Republic
      • 10.3.19.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.19.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.19.2.1 Market size, by oral, 2017 - 2030
        • 10.3.19.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.19.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.19.2.2 Market size, by topical, 2017 - 2030
        • 10.3.19.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.19.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.19.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.19.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.19.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.19.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.20 Finland
      • 10.3.20.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.20.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.20.2.1 Market size, by oral, 2017 - 2030
        • 10.3.20.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.20.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.20.2.2 Market size, by topical, 2017 - 2030
        • 10.3.20.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.20.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.20.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.20.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.20.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.20.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.3.21 Russia
      • 10.3.21.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.3.21.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.3.21.2.1 Market size, by oral, 2017 - 2030
        • 10.3.21.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.3.21.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.3.21.2.2 Market size, by topical, 2017 - 2030
        • 10.3.21.2.3 Market size, by rectal, 2017 - 2030
        • 10.3.21.2.4 Market size, by parenteral, 2017 - 2030
      • 10.3.21.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.3.21.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.3.21.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.3.21.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.4 Asia Pacific
    • 10.4.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.4.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.4.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.4.3.1 Market size, by oral, 2017 - 2030
        • 10.4.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.4.3.2 Market size, by topical, 2017 - 2030
      • 10.4.3.3 Market size, by rectal, 2017 - 2030
      • 10.4.3.4 Market size, by parenteral, 2017 - 2030
    • 10.4.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.4.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.4.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.4.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.8 Japan
      • 10.4.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.8.2.1 Market size, by oral, 2017 - 2030
        • 10.4.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.8.2.2 Market size, by topical, 2017 - 2030
        • 10.4.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.9 China
      • 10.4.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.9.2.1 Market size, by oral, 2017 - 2030
        • 10.4.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.9.2.2 Market size, by topical, 2017 - 2030
        • 10.4.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.10 India
      • 10.4.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.10.2.1 Market size, by oral, 2017 - 2030
        • 10.4.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.10.2.2 Market size, by topical, 2017 - 2030
        • 10.4.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.11 Singapore
      • 10.4.11.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.11.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.11.2.1 Market size, by oral, 2017 - 2030
        • 10.4.11.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.11.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.11.2.2 Market size, by topical, 2017 - 2030
        • 10.4.11.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.11.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.11.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.11.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.11.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.11.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.4.12 Australia
      • 10.4.12.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.4.12.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.4.12.2.1 Market size, by oral, 2017 - 2030
        • 10.4.12.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.4.12.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.4.12.2.2 Market size, by topical, 2017 - 2030
        • 10.4.12.2.3 Market size, by rectal, 2017 - 2030
        • 10.4.12.2.4 Market size, by parenteral, 2017 - 2030
      • 10.4.12.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.4.12.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.4.12.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.4.12.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.5 Latin America
    • 10.5.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.5.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.5.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.5.3.1 Market size, by oral, 2017 - 2030
        • 10.5.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.5.3.2 Market size, by topical, 2017 - 2030
      • 10.5.3.3 Market size, by rectal, 2017 - 2030
      • 10.5.3.4 Market size, by parenteral, 2017 - 2030
    • 10.5.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.5.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.5.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.5.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.5.8 Brazil
      • 10.5.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.5.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.5.8.2.1 Market size, by oral, 2017 - 2030
        • 10.5.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.5.8.2.2 Market size, by topical, 2017 - 2030
        • 10.5.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.5.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.5.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.5.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.5.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.5.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.5.9 Mexico
      • 10.5.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.5.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.5.9.2.1 Market size, by oral, 2017 - 2030
        • 10.5.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.5.9.2.2 Market size, by topical, 2017 - 2030
        • 10.5.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.5.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.5.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.5.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.5.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.5.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.5.10 Argentina
      • 10.5.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.5.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.5.10.2.1 Market size, by oral, 2017 - 2030
        • 10.5.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.5.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.5.10.2.2 Market size, by topical, 2017 - 2030
        • 10.5.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.5.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.5.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.5.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.5.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.5.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
  • 10.6 Middle East & Africa
    • 10.6.1 Market size, by country, 2017 - 2030 (USD Million)
    • 10.6.2 Market size, by therapeutic area, 2017 - 2030 (USD Million)
    • 10.6.3 Market size, by product, 2017 - 2030 (USD Million)
      • 10.6.3.1 Market size, by oral, 2017 - 2030
        • 10.6.3.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.3.1.2 Market size, by liquid preparation, 2017 - 2030
      • 10.6.3.2 Market size, by topical, 2017 - 2030
      • 10.6.3.3 Market size, by rectal, 2017 - 2030
      • 10.6.3.4 Market size, by parenteral, 2017 - 2030
    • 10.6.4 Market size, by application, 2017 - 2030 (USD Million)
    • 10.6.5 Market size, by compounding type, 2017 - 2030 (USD Million)
    • 10.6.6 Market size, by sterility, 2017 - 2030 (USD Million)
    • 10.6.7 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.8 Saudi Arabia
      • 10.6.8.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.8.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.8.2.1 Market size, by oral, 2017 - 2030
        • 10.6.8.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.8.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.8.2.2 Market size, by topical, 2017 - 2030
        • 10.6.8.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.8.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.8.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.8.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.8.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.8.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.9 UAE
      • 10.6.9.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.9.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.9.2.1 Market size, by oral, 2017 - 2030
        • 10.6.9.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.9.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.9.2.2 Market size, by topical, 2017 - 2030
        • 10.6.9.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.9.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.9.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.9.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.9.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.9.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.10 South Africa
      • 10.6.10.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.10.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.10.2.1 Market size, by oral, 2017 - 2030
        • 10.6.10.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.10.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.10.2.2 Market size, by topical, 2017 - 2030
        • 10.6.10.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.10.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.10.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.10.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.10.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.10.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.11 Qatar
      • 10.6.11.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.11.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.11.2.1 Market size, by oral, 2017 - 2030
        • 10.6.11.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.11.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.11.2.2 Market size, by topical, 2017 - 2030
        • 10.6.11.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.11.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.11.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.11.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.11.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.11.6 Market size, by distribution channel, 2017 - 2030 (USD Million)
    • 10.6.12 Kuwait
      • 10.6.12.1 Market size, by therapeutic area, 2017 - 2030 (USD Million)
      • 10.6.12.2 Market size, by product, 2017 - 2030 (USD Million)
        • 10.6.12.2.1 Market size, by oral, 2017 - 2030
        • 10.6.12.2.1.1 Market size, by solid preparation, 2017 - 2030
        • 10.6.12.2.1.2 Market size, by liquid preparation, 2017 - 2030
        • 10.6.12.2.2 Market size, by topical, 2017 - 2030
        • 10.6.12.2.3 Market size, by rectal, 2017 - 2030
        • 10.6.12.2.4 Market size, by parenteral, 2017 - 2030
      • 10.6.12.3 Market size, by application, 2017 - 2030 (USD Million)
      • 10.6.12.4 Market size, by compounding type, 2017 - 2030 (USD Million)
      • 10.6.12.5 Market size, by sterility, 2017 - 2030 (USD Million)
      • 10.6.12.6 Market size, by distribution channel, 2017 - 2030 (USD Million)

Chapter 11 Company Profiles

  • 11.1 Strategy dashboard, 2021
  • 11.2 Athenex Pharma Solutions (Athenex Inc.)
    • 11.2.1 Business overview
    • 11.2.2 Financial data
    • 11.2.3 Product landscape
    • 11.2.4 Strategic outlook
    • 11.2.5 SWOT analysis
  • 11.3 B. Braun SE
    • 11.3.1 Business overview
    • 11.3.2 Financial data
    • 11.3.3 Product landscape
    • 11.3.4 Strategic outlook
    • 11.3.5 SWOT analysis
  • 11.4 Clinigen Limited
    • 11.4.1 Business overview
    • 11.4.2 Financial data
    • 11.4.3 Product landscape
    • 11.4.4 Strategic outlook
    • 11.4.5 SWOT analysis
  • 11.5 Dougherty's Pharmacy, Inc.
    • 11.5.1 Business overview
    • 11.5.2 Financial data
    • 11.5.3 Product landscape
    • 11.5.4 Strategic outlook
    • 11.5.5 SWOT analysis
  • 11.6 Fagron
    • 11.6.1 Business overview
    • 11.6.2 Financial data
    • 11.6.3 Product landscape
    • 11.6.4 Strategic outlook
    • 11.6.5 SWOT analysis
  • 11.7 Fresenius Kabi
    • 11.7.1 Business overview
    • 11.7.2 Financial data
    • 11.7.3 Product landscape
    • 11.7.4 Strategic outlook
    • 11.7.5 SWOT analysis
  • 11.8 Institutional Pharmacy Solutions
    • 11.8.1 Business overview
    • 11.8.2 Financial data
    • 11.8.3 Product landscape
    • 11.8.4 Strategic outlook
    • 11.8.5 SWOT analysis
  • 11.9 Lorraine's Pharmacy
    • 11.9.1 Business overview
    • 11.9.2 Financial data
    • 11.9.3 Product landscape
    • 11.9.4 Strategic outlook
    • 11.9.5 SWOT analysis
  • 11.10 McGuff Company Inc. (McGuff Compounding Pharmacy Services)
    • 11.10.1 Business overview
    • 11.10.2 Financial data
    • 11.10.3 Product landscape
    • 11.10.4 Strategic outlook
    • 11.10.5 SWOT analysis
  • 11.11 Nephron Pharmaceuticals Corporation
    • 11.11.1 Business overview
    • 11.11.2 Financial data
    • 11.11.3 Product landscape
    • 11.11.4 Strategic outlook
    • 11.11.5 SWOT analysis
  • 11.12 Pencol Compounding Pharmacy
    • 11.12.1 Business overview
    • 11.12.2 Financial data
    • 11.12.3 Product landscape
    • 11.12.4 Strategic outlook
    • 11.12.5 SWOT analysis
  • 11.13 Rx3 Compounding Pharmacy
    • 11.13.1 Business overview
    • 11.13.2 Financial data
    • 11.13.3 Product landscape
    • 11.13.4 Strategic outlook
    • 11.13.5 SWOT analysis
  • 11.14 Triangle Compounding Pharmacies
    • 11.14.1 Business overview
    • 11.14.2 Financial data
    • 11.14.3 Product landscape
    • 11.14.4 Strategic outlook
    • 11.14.5 SWOT analysis
  • 11.15 Wedgewood Village Pharmacy, Inc.
    • 11.15.1 Business overview
    • 11.15.2 Financial data
    • 11.15.3 Product landscape
    • 11.15.4 Strategic outlook
    • 11.15.5 SWOT analysis